ADRX,BRVE Stock Price and Quote

Peers: ARWR ALNY IONS WVE ABUS DYN STOK SLN VKTX RNA

| Held by: VTI VXF VTWO TMED TDNA VTWG TSEE VTWV

Index	-
Market Cap	1.96B
Enterprise Value	1.90B
Income	-
Sales	-
Book/sh	-2.35
Cash/sh	3.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.98
Current Ratio	12.98
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.82
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Insider Own	59.08%
Insider Trans	8.56%
Inst Own	-
Inst Trans	12.57%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.05%
SMA50	-3.32%
SMA200	-3.32%
Trades

Shs Outstand	106.80M
Shs Float	45.36M
Short Float	2.56%
Short Ratio	1.41
Short Interest	1.16M
52W High	23.21 -23.65%
52W Low	16.61 6.68%
Volatility	7.28% -
ATR (14)	1.60
RSI (14)	41.51
Beta	-
Rel Volume	0.17
Avg Volume	825.58K
Volume	65,034

Perf Week	0.40%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-19.82%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	34.25
Prev Close	17.68
Price	17.72
Change %	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-26	Initiated	UBS	Buy	$35
Oct-20-26	Initiated	TD Cowen	Buy
Oct-20-26	Initiated	Morgan Stanley	Overweight	$32
Oct-20-26	Initiated	JP Morgan	Overweight	$38

Oct-01-26 04:15PM

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

(GlobeNewswire) -6.60%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Sep 28 '26	Buy	17.00	61,516	1,045,772	9,292,025	Sep 30 05:29 PM
GORDON CARL L	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:25 PM
ORBIMED ADVISORS LLC	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:45 PM
George Simeon	Director	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:43 PM

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Zhen Li Ph.D.

Chief Scientific OfficerDr. A. Robert MacLeod Ph.D.

CFO & Chief Business OfficerMr. Ryan Fisk M.B.A.

Ph.D.Dr. Christopher Claeboe M.B.A.

Chief Technology OfficerDr. Rui Zhu Ph.D.

BRVE Braveheart Bio Inc daily Stock Chart

Peers: CYTK EWTX MLYS NAMS TNYA BMY BBIO LXEO VERA TRVI

| Held by: VTI VXF SCHA ONEQ SCHB FMED VTWO TMED VTWG VTWV

Index	-
Market Cap	1.92B
Enterprise Value	2.01B
Income	-
Sales	-
Book/sh	-1.07
Cash/sh	1.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	15.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.63
Current Ratio	13.63
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.44
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 08 AMC
EPS/Sales Surpr.	-193.45% -

Insider Own	76.55%
Insider Trans	14.70%
Inst Own	-
Inst Trans	15.82%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.93%
SMA50	-11.71%
SMA200	-12.99%
Trades

Shs Outstand	90.04M
Shs Float	21.11M
Short Float	19.56%
Short Ratio	8.15
Short Interest	4.13M
52W High	32.00 -33.48%
52W Low	17.86 19.18%
Volatility	7.70% 9.20%
ATR (14)	1.73
RSI (14)	48.29
Beta	-
Rel Volume	0.18
Avg Volume	506.75K
Volume	40,958

Perf Week	13.76%
Perf Month	-8.92%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-29.52%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	45.25
Prev Close	21.48
Price	21.28
Change %	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-26	Initiated	TD Cowen	Buy
Aug-31-26	Initiated	Stifel	Buy	$45
Aug-31-26	Initiated	Jefferies	Buy	$48
Aug-31-26	Initiated	Goldman	Buy	$48
Aug-31-26	Initiated	Cantor Fitzgerald	Overweight	$40

Sep-16-26 04:30PM	Braveheart Bio to Participate in Stifel Cardiometabolic Forum (GlobeNewswire)
Sep-08-26 04:03PM	Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +9.99%
Sep-01-26 04:30PM	Braveheart Bio to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) -7.07%
07:00AM	Jefferies starts biopharma firm Braveheart at Buy after IPO (Investing.com)
04:05PM	Loading…
Aug-07-26 04:05PM	Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.23%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund IV, L.P.	10% Owner	Aug 07 '26	Buy	18.00	1,100,000	19,800,000	10,232,420	Aug 11 05:53 PM
Chimovits Erez	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:31 PM
ORBIMED ADVISORS LLC	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:27 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,920,000	34,560,000	11,640,546	Aug 07 05:25 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,680,000	30,240,000	10,185,478	Aug 07 05:25 PM
Rickey James Paul	Chief Financial Officer	Aug 07 '26	Buy	18.00	27,777	499,986	520,927	Aug 07 04:41 PM
Viehbacher Christopher	Director	Aug 07 '26	Buy	18.00	83,333	1,499,994	609,519	Aug 07 04:31 PM
Malek David I	Director	Aug 07 '26	Buy	18.00	4,166	74,988	533,845	Aug 07 04:31 PM
Anderson Michele A.	Chief Development Officer	Aug 07 '26	Buy	18.00	1,111	19,998	332,161	Aug 07 04:30 PM
Murdoch Travis	CEO and President	Aug 07 '26	Buy	18.00	83,333	1,499,994	2,940,670	Aug 07 04:30 PM
Lubner David Charles	Director	Aug 07 '26	Buy	18.00	55,555	999,990	55,555	Aug 07 04:30 PM

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

M.D.Dr. Travis Murdoch B.S.

Chief Financial OfficerMr. James Paul Rickey CPA

Chief Development OfficerMs. Michele A. Anderson

Chief Scientific OfficerMr. Marc Evanchik M.S.

VP & Head of LegalMs. Natalie Dement J.D.

ADRX

ADARx Pharmaceuticals Inc

BRVE

Braveheart Bio Inc

Upgrade your Finviz experience